.jpg "Mariarosaria Miranda, MA photo")
PhD student
Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands
Amsterdam, Noord-Holland, Netherlands
Mariarosaria Miranda is an Early Stage Researcher in the EDUC8 consortium and works in the Molecular Hematology department in Sanquin (Amsterdam, The Netherlands). Her projects focuses on exploring red blood cells (RBCs) as a novel tolerogenic approach for factor VIII inhibitors employing immunodominant FVIII derived peptides presented on MHC class II. To this extend, she has used bioinformatics tools to identify promiscuously presented FVIII peptides. To supplement this data-set, she has optimized a mass spectrometry based peptide presentation assay that detects more than 4000 HLA-DR and 2000 HLA-DP associated peptides, and over 100 HLA-DR and 10 HLA-DP4 presented FVIII peptides. Moreover, she has developed a strategy to target RBCs with FVIII derived peptides fused to a TAT cell-penetrating peptide. She has validated the TAT-FVIII peptides binding using flow cytometric techniques and microscopy. She assessed the RBCs phagocytosis by macrophages, and functional presentation of RBC bound peptides on MHC class II on the surface of macrophages. She is currently exploring the presentation of immunodominant FVIII peptides on MHC class II, and whether it results in tolerance induction. At this ISTH conference, she is presenting the main FVIII derived peptides detected and the targeting of RBCs in an oral talk.
Sunday, June 25, 2023
18:30 – 19:30 ET